Search

Displaying results 2771 - 2780 of 7452 in total
  1. Drug

    Aprocitentan

    go.drugbank.com/drugs/DB15059
    ApprovedInvestigational

    Endothelin receptor antagonism provides a novel therapeutic pathway for the management of patients with resistant hypertension. … Aprocitentan is a dual antagonist of endothelin receptors A and B used for treatment-resistant hypertension. It is the active metabolite of [macitentan].

  2. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    to be approved for this condition. … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist

  3. Drug

    Tuberculin purified protein derivative

    go.drugbank.com/drugs/DB11601
    Approved

    Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Tafenoquine

    go.drugbank.com/drugs/DB06608
    ApprovedInvestigational

    [A35690] Tafenoquine was further developed collaboratively between GlaxoSmithKline and Medicines for Malaria Venture.[A35677] It was FDA approved on July 20, 2018.[L3770] … [A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria.

  5. Drug

    Tandutinib

    go.drugbank.com/drugs/DB05465
    Investigational

    Approximately 25 to 30 percent of all adult AML patients have a mutation of the FLT3 gene. The use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration.

  6. Drug

    Carbamoylcholine

    go.drugbank.com/drugs/DB00411
    Approved

    [A226315] Carbamoylcholine was initially used as a treatment for migraines,[A226365] induction of diuresis,[A226370] and other parasympathetic effects.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Biguanide

    go.drugbank.com/drugs/DB13100
    ApprovedInvestigationalWithdrawn

    Biguanide has been investigated for the treatment of Diabetes Mellitus.

  8. Drug

    DFV890

    go.drugbank.com/drugs/DB16461
    Investigational

    DFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic

    Categories: Experimental Unapproved Treatments for COVID-19
  9. Drug

    Odronextamab

    go.drugbank.com/drugs/DB16684
    ApprovedInvestigational

    [A254192] Odronextamab received its first approval in the European Union on August 26, 2024, for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma … Odronextamab is a hinge-stabilized, fully human immunoglobulin G4 (IgG4)-based CD20×CD3 bispecific antibody currently evaluated for the treatment of relapsed/refractory (R/R) B-Cell non-Hodgkin lymphoma

  10. Drug

    rhThrombin

    go.drugbank.com/drugs/DB04923
    ApprovedWithdrawn

    ZymoGenetics is developing rhThrombin, a recombinant form of human thrombin that is not derived from animal or human blood, as an aid to controlling bleeding during surgery. … The production of recombinant proteins is not dependent on the availability of blood from animals or human donors and can be scaled-up to meet market demand.